SEGMENT INFORMATION

3 Months Ended

Mar. 31, 2025

Segment Reporting [Abstract]

SEGMENT INFORMATION

NOTE 13 – SEGMENT INFORMATION 

The Company has one operating and reporting segment, that develops, manufactures and markets products for the treatment of carotid artery disease and other vascular disease, including the Company’s proprietary CGuard™ stent platform. The Company’s Chief Operating Decision Maker (“CODM”), who is the CEO evaluates the Company’s performance based on its internal reporting which is consistent with the presentation in the Company’s consolidated financial statements. Accordingly, our CODM uses consolidated net income to measure segment profit or loss, allocate resources, and assess performance.

The CODM examines, within each operational function the employee salaries including the bonus and share based compensation. In addition, the CODM examines the clinical trials expenses within the research and development operations.

	Three months ended March 31,
	2025			2024
Revenues		1,529			1,511
Cost of Revenues:
Material and Labor		1,025			974
Other cost of revenues		212			245
Total Cost of Revenues		1,237			1,219
Research and development (R&D)
Payroll and Benefits		855			683
Share based compensation		668			468
Clinical trials		1,160			784
Other R&D		1,376			690
Total Research and development		4,059			2,625
Selling and marketing (S&M)
Payroll and Benefits		1,979			822
Share based compensation		217			250
Other S&M		554			165
Total Selling and marketing		2,750			1,237
General and administrative (G&A)
Payroll and Benefits		1,676			915
Share based compensation		1,779			1,784
Other G&A		1,488			1,145
Total General and administrative		4,943			3,844
Financial Income, net;		294			382
Segment net Loss		(11,166	)		(7,032	)